Expression of estrogen receptor α mRNA and protein variants in human endometrial carcinoma

Gynecologic Oncology

Volumn 74, Issue 1, 1999, Pages 38-47

  Jazaeri, Omid ^a   Shupnik, Margaret A ^b   Jazaeri, Amir A ^a   Rice, Laurel W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TAMOXIFEN;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; DRUG RECEPTOR BINDING; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032789378     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5404     Document Type: Article

References (49)

1. Evans R M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
2. Greene G L, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science. 231:1986;1150-1157.
3. Green S, Walter P, Kumar V, Crust A, Bornert J-M, Argos P, Chambon P. Human oestrogen receptor cDNA; sequence, expression and homology to v-erb-A. Nature. 320:1986;134-139.
4. Kumar V, Green S, Stack G, Berry M, Jin J, Chambon P. Functional domains of the human estrogen receptor. Cell. 51:1982;941-951.
5. Beato M. Gene regulation by steroid hormones. Cell. 56:1989;335-344.
6. Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell. 55:1988;145-156.
7. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392:1996;49-53.
8. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson J. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 82:1997;4258-4265.
9. Pace P, Taylor J, Suntharalingam S, Coombes R C, Ali S. Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α J Biol Chem. 272:1997;25832-25838.
10. R-1 compared to the parental MCF7 cell line. Mol Cell Endocrinol. 109:1995;197-207.
11. Graham M L II, Krett N L, Miller L A, Leslie K K, Gordon D F, Wood W M, Wei L L, Horowitz K B. T47Dco cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res. 51:1990;105-109.
12. Murphy L C. Estrogen receptor variants in human breast cancer. Mol Cell Endocrinol. 74:1990;C83-C86.
13. Fuqua S AW, Fitzgerald S D, Chamness G C, Tandon A K, McDonnell D P, Nawaz Z, O'Mally D W, McQuire W L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 51:1991;105-109.
14. Zhang Q X, Hilsenbeck S G, Fuqua S AW, Borg A. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 59:1996;251-260.
15. Leygue E R, Watson P H, Murphy L C. Estrogen receptor variants in normal human mammary tissue. J Natl Cancer Inst. 88:1996;284-290.
16. Fasco M J. Quantitation of estrogen receptor mRNA and its alternatively spliced mRNAs in breast tumor cells and tissues. Anal Biochem. 245:1996;167-178.
17. Huang A, Leygue E R, Snell L, Murphy L C, Watson P H. Expression of estrogen receptor variant messenger RNAs and determinations of estrogen receptor status in human breast cancer. Am J Pathol. 150:1997;1827-1833.
18. Daffada A AI, Johnston S RD, Smith I E, Detre S, King N, Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status. Cancer Res. 55:1995;288-293.
19. Rea D, Parker M G. Effects of an exon 5 variant of the estrogen receptor in MCF7 breast cancer cells. Cancer Res. 56:1996;1556-1563.
20. Castles C G, Fuqua S AW, Klotz D M, Hill S M. Expression of a constitutively active estrogen receptor variant in the estrogen receptor negative BT-20 human breast cancer cell line. Cancer Res. 53:1993;5934-5939.
21. Gottardis M M, Robertson S P, Satayaswaroop J P, Jordan V C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48:1988;812-815.
22. Malfetano J H. Tamoxifen: associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol. 39:1990;82.
23. Cohen I, Altaras M M, Shapira J, Tepper R, Beyth Y. Postmenopausal tamoxifen treatment and endometrial pathology. Obstet Gynecol Surv. 49:1994;823-828.
24. Webb P, Lopez G N, Uht R M, Kushner P J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol. 8:1995;443-456.
25. Cook L S, Weiss N S, Schwartz S M, White E, McKnight B, Moore D E, Daling J R. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 87:1995;1359-1364.
26. Heaney R P, Draper M W. Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab. 82:1997;3425-3429.
27. Bjarnason N H, Haarbo J, Byrjalsen I, Kauffman R F, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation. 96:1997;1964-1969.
28. Lundeen S G, Carver J M, McKean M L, Winneker R C. Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels. Endocrinology. 138:1997;1552-1558.
29. Delmas P D, Bjarnason N H, Mitlak B H. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337:1997;1641-1647.
30. Hirata S, Yamada-Mouri N, Nara M, Takizawa M, Ito H, Kato J. Presence of alternatively spliced-estrogen receptor mRNA variants in normal human endometrium and endometrial cancer. Endocrinol J. 42:1995;289-293.
31. Fujimoto J, Hori M, Ichigo S, Nishigaki M, Itoh T, Tamaya T. Expression of aberrant estrogen receptor mRNA in endometrial cancers in comparison with normal endometria. Hormone Res. 42:1994;116-119.
32. Hu C, Hyder S M, Needleman D S, Baker V V. Expression of estrogen receptor variants in normal and neoplastic human uterus. Mol Cell Endocrinol. 118:1996;173-179.
33. Fujimoto J, Ichigo S, Hirose R, Hori M, Tamaya T. Expression of estrogen receptor exon 5 splice variant (ER E5SV) mRNA in gynecologic cancers. J Steroid Biochem Mol Biol. 60:1997;25-30.
34. Rice L W, Jazaeri A A, Shupnik M A. Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma. Gynecol Oncol. 65:1997;149-157.
35. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
36. Al Saati T, Clamens S, Cohen-Knafo E, Faye J C, Prats H, Coindre J M. Production of monoclonal antibodies to human estrogen receptor protein (ER) using recombinant ER (RER). Int J Cancer. 55:1993;651-654.
37. Anzick S L, Kononen J, Walker R L, Azorsa D, Tanner M M, Guan X Y, Suter G. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 277:1997;965-968.
38. Weigel N L, Beck C A, Estes P A, Prendergast P, Altmann M, Christensen K, Edwards D P. Ligands induce conformational changes in the carboxy-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol Endocrinol. 6:1992;1585-1597.
39. Fisher B, Costantino J P, Redmond C K, Fisher E R, Wickerham D L, Cronin W M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project B-14. J Natl Cancer Inst. 86:1994;527-537.
40. Osborne C K, Coronodo E, Allred D C, Wiebe V, DeGregorio M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst. 83:1991;1477-1482.
41. Daly R J, Darbre P D. Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res. 50:1990;5868-5875.
42. Mikicek R J. Steroid receptor variants in their potential role in cancer. Semin Cancer Biol. 5:1994;369-379.
43. Koehorst S A, Cox J J, Donker G H, DaSilva S L, Burbach J PH, Thijssen J HH, Blankstein M A. Functional analysis of an alternatively spliced estrogen receptor lacking exon 4 isolated from MCF-7 breast cancer cells and meningioma tissue. Mol Cell Endocrinol. 101:1994;237-245.
44. Wang Y, Miksicek R J. Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol. 5:1991;1707-1715.
45. Fuqua S AW, Fitzgerald S D, Allred D C, Elledge R M, Nawaz Z, Mcdonnell D P, O'Malley B W, Greene G L, McGuire W L. Inhibition of estrogen receptor action by a naturally occuring variant in human breast tumors. Cancer Res. 52:1992;483-486.
46. Klotz D M, Castles C G, Fuqua S AW, Spriggs K L, Hill S M. Differential expression of wild-type and variant ER mRNAs by stocks of MCF-7 breast cancer cells may account for the differences in estrogen responsiveness. Biochem Biophys Res Commun. 210:1995;609-615.
47. Katzenellenbogen B S. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol Reprod. 54:1996;287-293.
48. Ignar-Trowbridge D M, Pimentel M, Parker M G, McLachlan J A, Korach K S. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology. 137:1996;1735-1744.
49. Chaidarum S S, Alexander J M. A tumor-specific truncated estrogen receptor splice variant enhances estrogen-stimulated gene expression. Mol Endocrinol. 12:1998;1355-1366.